MDxHealth SA (NASDAQ:MDXH) Stock Now Rated “Hold” by Wall Street Analysts

MDxHealth SA (NASDAQ:MDXH) has received an average recommendation of “Hold” from the five analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $2.17.

A number of equities research analysts have weighed in on MDXH shares. Wall Street Zen raised shares of MDxHealth to a “sell” rating in a report on Saturday, August 15th. Lake Street Capital set a $3.00 price objective on shares of MDxHealth and gave the stock a “buy” rating in a research note on Friday, August 14th. BTIG Research dropped their target price on shares of MDxHealth from $4.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, August 21st. Finally, Weiss Ratings lowered shares of MDxHealth from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th.

MDxHealth Price Performance

MDXH opened at $0.58 on Friday. The business has a 50 day moving average price of $0.63 and a two-hundred day moving average price of $1.00. The company has a market capitalization of $28.73 million, a price-to-earnings ratio of -0.81 and a beta of 1.68. MDxHealth has a 1-year low of $0.40 and a 1-year high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. The firm had revenue of $27.21 million during the quarter, compared to the consensus estimate of $26.14 million. Equities analysts expect that MDxHealth will post -0.49 EPS for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

Institutional investors and hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC acquired a new stake in MDxHealth during the 2nd quarter worth about $82,000. Perkins Capital Management Inc. grew its stake in MDxHealth by 7.1% during the 1st quarter. Perkins Capital Management Inc. now owns 1,476,441 shares of the company’s stock valued at $3,396,000 after acquiring an additional 97,500 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of MDxHealth by 21.8% in the 1st quarter. Renaissance Technologies LLC now owns 304,700 shares of the company’s stock valued at $701,000 after purchasing an additional 54,600 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of MDxHealth by 213.9% in the 1st quarter. Bank of America Corp DE now owns 43,492 shares of the company’s stock valued at $100,000 after purchasing an additional 29,638 shares during the period.

About MDxHealth

MDxHealth is a precision diagnostics company focused on improving the detection, diagnosis and management of cancer. The company develops and commercializes molecular and genomic tests designed to help physicians assess cancer risk, guide treatment decisions and monitor patients, with a primary focus on urological cancers.

Its product portfolio includes ConfirmMDx, a tissue-based test intended to help identify men who may have clinically significant prostate cancer after a prior negative biopsy; SelectMDx, a urine-based test that helps assess the likelihood of clinically significant prostate cancer; and ResolveMDx, a molecular test designed to support prostate cancer risk assessment.